Gene therapy of multiple sclerosis using interferon β-secreting human bone marrow mesenchymal stem cells

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Ryu, Chung Heon ^a   Park, Kwang Ywel ^a   Hou, Yun ^b   Jeong, Chang Hyun ^b   Kim, Seong Muk ^a   Jeun, Sin Soo ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD BRAIN BARRIER PERMEABILITY; BONE MARROW CELL; CELL INFILTRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLUORESCENCE IMAGING; GENE TARGETING; GENE THERAPY; HISTOPATHOLOGY; IMMUNOMODULATION; IN VIVO STUDY; INHIBITION KINETICS; MEMBRANE PERMEABILITY; MESENCHYME CELL; MULTIPLE SCLEROSIS; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; ANIMAL; CYTOLOGY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; PATHOLOGY; SECRETION (PROCESS);

ANIMALS; BONE MARROW CELLS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MULTIPLE SCLEROSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878160786     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/696738     Document Type: Article

References (26)

1. Calabresi P. A., Diagnosis and management of multiple sclerosis. The American Family Physician 2004 70 10 1935 1944 2-s2.0-8844244694 (Pubitemid 39532194)
2. Castro-Borrero W., Graves D., Frohman T. C., Flores A. B., Hardeman P., Logan D., Orchard M., Greenberg B., Frohman E. M., Current and emerging therapies in multiple sclerosis: a systematic review. Therapeutic Advances in Neurological Disorders 2012 5 4 205 220 10.1177/1756285612450936
3. Polman C. H., Uitdehaag B. M. J., New and emerging treatment options for multiple sclerosis. The Lancet Neurology 2003 2 9 563 566 2-s2.0-0043022062 10.1016/S1474-4422(03)00505-2 (Pubitemid 36994996)
4. Swanborg R. H., Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clinical Immunology and Immunopathology 1995 77 1 4 13 2-s2.0-0028840828
5. Pittenger M. F., Mackay A. M., Beck S. C., Jaiswal R. K., Douglas R., Mosca J. D., Moorman M. A., Simonetti D. W., Craig S., Marshak D. R., Multilineage potential of adult human mesenchymal stem cells. Science 1999 284 5411 143 147 2-s2.0-0033515827 10.1126/science.284.5411.143 (Pubitemid 29282067)
6. Abumaree M., Al Jumah M., Pace R. A., Kalionis B., Immunosuppressive properties of mesenchymal stem cells. Stem Cell Reviews and Reports 2012 8 2 375 392 10.1007/s12015-011-9312-0
7. Lim J., Jeong C., Jun J., Kim S., Ryu C., Hou Y., Oh W., Chang J., Jeun S.-S., Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia. Stem Cell Research and Therapy 2011 2 5, article 38 10.1186/scrt79
8. Le Blanc K., Rasmusson I., Sundberg B., Götherström C., Hassan M., Uzunel M., Ringdén O., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet 2004 363 9419 1439 1441 2-s2.0-2342482526 10.1016/S0140-6736(04)16104-7 (Pubitemid 38586721)
9. Bai L., Lennon D. P., Eaton V., Maier K., Caplan A. I., Miller S. D., Miller R. H., Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. GLIA 2009 57 11 1192 1203 2-s2.0-65649113921 10.1002/glia.20841
10. Zhang J., Li Y., Chen J., Cui Y., Lu M., Elias S. B., Mitchell J. B., Hammill L., Vanguri P., Chopp M., Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Experimental Neurology 2005 195 1 16 26 2-s2.0-23644458723 10.1016/j.expneurol.2005.03.018 (Pubitemid 41116810)
11. Manfredonia F., Pasquali L., Dardano A., Ludice A., Murri L., Monzani F., Review of the clinical evidence for interferon β la (Rebif) in the treatment of multiple sclerosis. Neuropsychiatric Disease and Treatment 2008 4 2 321 336 2-s2.0-44049094579 (Pubitemid 351711928)
12. Dhib-Jalbut S., Marks S., Interferon- β mechanisms of action in multiple sclerosis. Neurology 2010 74 supplement 1 S17 S24 2-s2.0-74249112995 10.1212/WNL.0b013e3181c97d99
13. Pan W., Banks W. A., Kastin A. J., Permeability of the blood-brain and blood-spinal cord barriers to interferons. Journal of Neuroimmunology 1997 76 1-2 105 111 2-s2.0-0030992694 10.1016/S0165-5728(97)00034-9 (Pubitemid 27272635)
14. Kim A. M., Lim J. Y., Park S. I., Jeong C. H., Oh J. H., Jeong M., Oh W., Park S. H., Sung Y. C., Jeun S. S., Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Research 2008 68 23 9614 9623 2-s2.0-57149088465 10.1158/0008-5472.CAN- 08-0451
15. Goldstein D., Sielaff K. M., Storer B. E., Brown R. R., Datta S. P., Witt P. L., Teitelbaum A. P., Smalley R. V., Borden E. C., Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon- β serine. Journal of the National Cancer Institute 1989 81 14 1061 1068 2-s2.0-0024318227 (Pubitemid 19175140)
16. Walther E. U., Hohlfeld R., Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999 53 8 1622 1627 2-s2.0-0033544299 (Pubitemid 29530329)
17. Seo J. H., Cho S.-R., Neurorestoration induced by mesenchymal stem cells: potential therapeutic mechanisms for clinical trials. Yonsei Medical Journal 2012 53 6 1059 1067 10.3349/ymj.2012.53.6.1059
18. D'Intino G., Paradisi M., Fernandez M., Giuliani A., Aloe L., Giardino L., Calzà L., Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis rats. Proceedings of the National Academy of Sciences of the United States of America 2005 102 8 3070 3075 2-s2.0-14544273721 10.1073/pnas.0500073102 (Pubitemid 40299917)
19. Azoulay D., Mausner-Fainberg K., Urshansky N., Fahoum F., Karni A., Interferon- β therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism. Journal of Neuroimmunology 2009 211 1-2 114 119 2-s2.0-67349201042 10.1016/j.jneuroim.2009.04.004
20. Villoslada P., Hauser S. L., Bartke I., Unger J., Heald N., Rosenberg D., Cheung S. W., Mobley W. C., Fisher S., Genain C. P., Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. Journal of Experimental Medicine 2000 191 10 1799 1806 2-s2.0-0034657843 10.1084/jem.191.10.1799 (Pubitemid 30331576)
21. Kraus J., Voigt K., Schuller A. M., Scholz M., Kim K. S., Schilling M., Schäbitz W. R., Oschmann P., Engelhardt B., Interferon- β stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro. Multiple Sclerosis 2008 14 6 843 852 2-s2.0-48349131669 10.1177/1352458508088940
22. Kraus J., Ling A. K., Hamm S., Voigt K., Oschmann P., Engelhardt B., Interferon- β stabilizes barrier characteristics of brain endothelial cells in vitro. Annals of Neurology 2004 56 2 192 205 2-s2.0-3843101531 10.1002/ana.20161 (Pubitemid 39037915)
23. Nauta A. J., Fibbe W. E., Immunomodulatory properties of mesenchymal stromal cells. Blood 2007 110 10 3499 3506 2-s2.0-36348977575 10.1182/blood-2007-02-069716 (Pubitemid 350159613)
24. Knoepfler P. S., Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 2009 27 5 1050 1056 2-s2.0-66149179125 10.1002/stem.37
25. Connick P., Kolappan M., Crawley C., Webber D. J., Patani R., Michell A. W., Du M.-Q., Luan S.-L., Altmann D. R., Thompson A. J., Compston A., Scott M. A., Miller D. H., Chandran S., Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. The Lancet Neurology 2012 11 2 150 156 10.1016/S1474-4422(11)70305-2
26. Lee J. S., Hong J. M., Moon G. J., Lee P. H., Ahn Y. H., Bang O. Y., STARTING collaborators, A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010 28 6 1099 1106 2-s2.0-77956638921 10.1002/stem.430